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Sulforhodamine 101, a widely 
used astrocyte marker, can induce 
cortical seizure-like activity at 
concentrations commonly used
Rune Rasmussen1,2, Maiken Nedergaard1,2 & Nicolas Caesar Petersen1,3,4
Sulforhodamine 101 (SR101) is a preferential astrocyte marker widely used in 2-photon microscopy 
experiments. Here we show, that topical loading of two commonly used SR101 concentrations, 100 μM 
and 250 μM when incubated for 10 min, can induce seizure-like local field potential (LFP) activity in both 
anaesthetized and awake mouse sensori-motor cortex. This cortical seizure-like activity develops in 
less than ten minutes following topical loading, and when applied longer, these neuronal discharges 
reliably evoke contra-lateral hindlimb muscle contractions. Short duration (<1 min) incubation of 
100 μM and 250 μM SR101 or application of lower concentrations 25 μM and 50 μM of SR101, incubated 
for 30 and 20 min, respectively, did not induce abnormal LFP activity in sensori-motor cortex, but did 
label astrocytes, and may thus be considered more appropriate concentrations for in vivo astrocyte 
labeling. In addition to label astrocytes SR101 may, at 100 μM and 250 μM, induce abnormal neuronal 
activity and interfere with cortical circuit activity. SR101 concentration of 50 μM or lower did not induce 
abnormal neuronal activity. We advocate that, to label astrocytes with SR101, concentrations no higher 
than 50 μM should be used for in vivo experiments.
The fluorescent indicator dye sulforhodamine 101 (SR101) is a water-soluble compound, widely used for label-
ling of astrocytes for in vitro and in vivo 2-photon microscopy experiments1–5 (see Supplementary Table S1) and 
recently of oligodendrocytes6.
When used for in vivo microscopy, SR101 is routinely applied topically to the exposed cortex, from where it is 
taken up by astrocytes7 and diffuses through the astrocyte syncytium via gap junctions, brightly labelling astro-
cyte somata, processes and perivascular end-feet8. SR101 has in particular been used in combination with loading 
of chemical Ca2+ indicators such as Oregon Green 488 BAPTA-1 AM to unambiguously distinguishing between 
neuronal and astrocytic Ca2+ signals1,3.
We and others have previously described bioactive effects of SR101 on excitatory neuronal activity9,10. In hip-
pocampal slices, pyramidal CA1 neurones showed long-term potentiation of intrinsic excitability and enhanced 
synaptic efficacy following a short period of SR101 application9. Intra-neuronal recordings indicated that the 
increased excitability was a consequence of lowering the threshold for evoking action potentials and was observed 
following application of just 1 μ M SR101 for ten minutes.
The original publication by Nimmerjahn and colleagues reported that SR101 does not induce phototoxicity 
over hours, days and weeks8. Here we have combined SR101 loading with recordings of the local field potential 
(LFP) during the labeling period to interrogate if SR101 causes changes in cortical neuronal activity in vivo.
We explored the effects of topical SR101 application on neuronal activity in layer II of primary sensori-motor 
cortical areas (S1-M1) of adult anaesthetized or awake mice. We show that spontaneous seizure-like LFP activity 
develops within less than ten minutes following cortical exposure to 100 μ M SR101 for ten minutes, a commonly 
used dosage for astrocyte labelling (see Supplementary Table S1). This S1-M1 seizure-like neuronal activity was 
accompanied with a reduction in low-frequency power, and simultaneous increase in higher-frequency power in 
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the LFP. When exposing the cortex to 250 μM SR101 for ten minutes the seizure-like activity developed within 
five minutes and ceased after about 45 minutes. In addition, we show that SR101-induced seizure-like activity in 
S1-M1 is sufficiently potent to drive a motor output, recorded as compound action potentials in the sciatic nerve 
of the contra-lateral hindlimb or by observation of movement. Finally, we show that 25 μ M and 50 μ M SR101 
application, incubated for 30 or 20 minutes respectively, or 100 μ M and 250 μ M incubated for one minute, does 
not induce abnormal cortical LFP activity, and may thus be considered as safe dosages.
Results
SR101 can induce seizure-like LFP activity in anaesthetised mice. We first recorded LFPs in S1-M1 
of ketamine (120 mg kg–1) and xylazine (10 mg kg–1) (KX) anesthetized mice while topically applying 100 μ M or 
250 μ M SR101 for 10 minutes (Fig. 1a). In a subset of experiments, we included recordings of the electroneuro-
gram (ENG) from the contra-lateral sciatic nerve, to provide a measure of cortical-evoked motor output (Fig. 1a), 
in addition video recordings were obtained to document the motor activity (see Supplementary Videos S1–S3). 
Following topical application of SR101, astrocytes exhibited a time-dependent increase in SR101 fluorescent 
intensity, with a marked increase occurring ~10–20 minutes following application (Fig. 1b). Simultaneous LFP 
recordings in S1-M1 layer II revealed that large synchronized potentials, mimicking epileptic seizure activity in 
terms of individual event amplitude11–13 and event interval14–16, appeared within 5–10 minutes following topical 
100 μ M SR101 application (Fig. 1c).
Figure 1. SR101 can induce seizure-like activity in anaesthetized mice. (a) Experimental setup and 
craniotomy above primary sensori-motor cortex (S1-M1). (b) Astrocytic SR101 uptake time course. (c) Upper, 
LFP during development of seizure-like activity in S1-M1 following 100 μ M SR101 loading (10 min incubation). 
Lower, frequency power spectrograms from period 1 and 2 from LFP above. (d) Histograms showing individual 
seizure-like event amplitudes and intervals. (e) Graph showing dose-dependency of seizure-like activity onset 
and cessation. Statistical difference was assessed using an unpaired Welch’s t-test. (f) Left, simultaneous S1-M1 
LFP and ENG following 250 μ M SR101 application (10 min incubation). Right, graph showing cumulative 
number of ENG events as a function of seizure-like LFP events. Correlation was assessed using a Pearson’s 
correlations test.
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The seizure-like activity was correlated with a reduction in low-frequency power (1–4 Hz) and a slight increase 
in higher-frequency power (12–30 Hz) (Fig. 1c and Supplementary Fig. S1). Such increases in higher-frequency 
power bands have previously been showed in animal models using kainate or optogenetics to evoke epileptic 
acivity13,17.
Similar changes in cortical LFP activity were not recorded under control conditions (see Supplementary Fig. S2). 
An example of a non-filtered recording displaying the artefacts evoked by application and wash out of SR101 
10 min later is provided in Supplementary Fig. S3. The seizure-like activity displayed a gradual build-up in 
amplitude, similar to prevously shown during 4-AP-induced epilepsy15, with the individual seizure-like events 
exhibiting an average amplitude of 1.64 ± 0.67 mV and average event interval of 1.01 ± 0.88 s (Fig. 1d), similar 
to previous reports using caged 4-AP, kainate or optogenetics to evoke seizures11–13. The term “seizure-like” was 
chosen based on the LFP’s resembles to previously published LFP activity during epileptiform activity (i.e. event 
amplitude, event frequency and 12–30 Hz LFP power band increase), induced by commonly used epilepsy models 
such as kainate, 4-AP or kindling12,15,18. However, due to the lack of mechanistic insight to what is triggering the 
abnormal neuronal discharges following SR101 application, we chose “seizure-like”, as opposed to simply “epi-
leptiform” or “seizure”.
In many publications, SR101 is applied topically at concentrations ranging from 1 μ M to 1 mM 
(see Supplementary Table S1), most commonly between 100–300 μ M4,15,19,20, and incubated for 1–60 minutes 
(see Supplementary Table S1), often for 10–30 minutes15,20,21. SR101 induced a dose-dependent onset and ces-
sation of the cortical seizure-like LFP activity (Fig. 1e); at a loading concentration of 250 μ M (incubated for 
10 min), seizure-like activity appeared at 5.16 ± 3.41 min, but first 10.31 ± 5.1 min after application of 100 μ M 
(incubated for 10 min) SR101 (Unpaired Welch’s t-test, t = 2.819 df = 9.771, P = 0.0186). The seizure-like LFP 
activity disappeared after 47.50 ± 19.41 min and 32.83 ± 12.38 min following SR101 application, for 250 μ M and 
100 μ M SR101, respectively (Unpaired Welch’s t-test, t = 2.292 df = 15.91, P = 0.0359). Muscle twitches occurring 
in the contra-lateral hindlimb was observed ~20 minutes following topical SR101 application (see Supplementary 
Videos S1–S3). To assess whether the movement of the contra-lateral hindlimb originated from S1-M1, we 
obtained simultaneous LFP recordings in S1-M1 and ENG from the contra-lateral sciatic nerve (Fig. 1a). These 
recordings showed that S1-M1 SR101 application (250 μ M, ten minute incubation) correlated with arrival of 
compound action potentials in the sciatic nerve, and that individual seizure-like LFP events and ENG com-
pound action potential events were almost perfectly matched in a 1:1 ratio (Fig. 1f) (Pearsons’s correlation test, 
R2 = 0.99). An example of a longer recording is provided in Supplementary Fig. S4. A compound structurally 
similar to SR101, but with a SO3H group replaced by SO2NHNH222, is Texas Red, also used to label astrocytes8,23. 
Opposite to SR101 did topical Texas Red application (100 μ M and 500 μ M, 15 min and 10 min incubation time, 
respectively) not evoke any seizure-like LFP activity (see Supplementary Fig. S6). Taken together, these exper-
iments show that topical SR101 application can have pronounced effects on cortical neuronal activity when 
applied at commonly used loading concentrations, i.e. 100 μ M and 250 μ M, in anaesthetized mice.
SR101 can induce seizure-like LFP activity in awake mice. Anesthesia is known to have anti-epileptic 
effects24 and anesthesia markedly changes the membrane potential dynamics of neurones25. Moreover, in vivo 
2-photon microscopy experiments are increasingly based on analysis of awake animals4.
We therefore analyzed the effects of SR101 application in awake non-anaesthetized mice (Fig. 2a). Following 
preparation of the cranial window the mice were allowed to wake up from the anesthesia for 1 hour and wake-
fulness was then confirmed by decreased 1–4 Hz power and increased 12–30 Hz power in the LFP26 as well as 
by visual confirmation (Fig. 2b,c and Supplementary Fig. 7a–c). When we recorded LFPs in S1-M1 of awake 
mice we again observed large synchronised seizure-like potentials occuring following 100 μ M (10 min incuba-
tion) SR101 application (Fig. 2d). Note that movement artefacts were not removed from the LFP trace shown in 
Fig. 2d. This seizure-like activity was correlated with a drop in low-frequency power (1–4 Hz) and an increase in 
higher-frequency power (12–30 Hz) (Fig. 2d and Supplementary Fig. S1) similar to seen in Fig. 1b and previous 
epilepsy publications13,17. The individual seizure-like events in awake mice exhibited an average amplitude of 
1.4 ± 0.82 mV and average event intervals of 0.83 ± 0.75 s (Fig. 2e). Thus, the average seizure-like event ampli-
tude was 0.24 mV smaller (Unpaired Welch’s t-test, t = 1.632 df = 8.605, P = 0.1387) and the event interval 0.16 s 
shorter (Unpaired Welch’s t-test, t = 2.181 df = 9.934, P = 0.0543) than in anaesthetized mice. Overall, this exper-
iment expands the finding that SR101 evoke seizure-like cortical activity to awake animals, potentially making 
it useful as an epileptogenic agent for future in vivo experiments investigating cortical epilepsy, conditioned that 
SR101’s mechanism of action will be revealed in future experiments.
Lower concentrations or shorter incubation time does not evoke abnormal cortical LFP activity. 
The original publication by Nimmerjahn and colleagues, showing the ability of SR101 to label cortical astro-
cytes in vivo, recommended using 25–100 μ M SR101 and incubation for one to five minutes8. However, from 
Supplementary Table S1 provided in the supplementary material, it appears that a large fraction of publications 
use concentrations higher than this (see Supplementary Table S1). In Figs 1 and 2 we show that topical loading of 
100 μ M and 250 μ M SR101 (10 min incubation) may induce abnormal cortical neuronal activity, an effect that ide-
ally is undesireable. Thus, in the final experiment we tested the effect of lower concentrations, i.e. 25 μ M and 50 μ M, 
of SR101 and concentrations of 100 μ M and 250 μ M incubated for one minute on cortical neuronal activity. 
We observed bright labelling of cortical astrocytes using either 100 μ M (1 min incubation) or 50 μ M (10 min incuba-
tion) SR101 (Fig. 3b,d). Contrary to the previous experiments, we did not observe any abnormal LFP activity in the 
anaesthetised cortex following loading, despite leaving the SR101 on for 30 min and 20 min for 25 μ M and 50 μ M, 
respectively (Fig. 3c–d and Supplementary S5). Non-filtered recordings displaying the application and wash out 
induced artefacts, together with power spectrograms, are provided in Supplementary Fig. S5. Thus, from these 
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experiments it appears that concentrations of 50 μ M, or less, SR101 does not induce abnormal cortical neuronal 
activity, but still sufficiently labels astrocytes (summarised in Fig. 3d).
Discussion
Here we report that SR101, a widely used fluorescent dye for specific labelling of astrocytes, possess potent bioac-
tive effects able to change cortical neuronal activity in vivo following topical loading.
Currently the mechanism for how SR101 triggers the observed change in cortical neuronal activity is 
unknown. The two most likely hypotheses may be that: (1) SR101 has a direct effect on cortical neurones, or 
(2) SR101 has an indirect effect on neuronal activity via an astrocyte-mediated mechanism. We have previously 
shown, that in hippocampal slices SR101 induces a direct effect on pyramidal neurone membrane structures, 
leading to a reduction in action potential firing threshold, and a long-term increase in neuronal excitability and 
synaptic efficacy9. This finding is in agreement with a similar experiment performed in hippocampal slices10. Here 
the authors showed that SR101 markedly increased the excitability of pyramidal neurones as well as induced mon-
osynaptic long-term potentiation of synaptic efficacy in hippocampal area CA1. These effects developed already 
after five minutes following 100 μ M or 25 μ M SR101 bath application10. This time course agrees with our find-
ing that SR101-induced seizure-like LFP activity develops within five to ten minutes following topical loading, 
depending on the applied concentration (Fig. 1). This rather rapid time course favours a direct SR101-mediated 
effect on neurones. We observed that cortical astrocytes starts to appear bright under the 2-photon microscope 
within ten to twenty minutes following 100 μ M SR101 application (Fig. 1), similar to what Nimmerjahn and 
colleagues reported in the original publication8. If the SR101-triggered effect on neuronal LFP activity was via 
an astrocyte-dependent intra-cellular mechanism, one might expect that SR101 uptake into cortical astrocytes 
preceded that of LFP changes; this did not seem to be the case. Thus, it appears more likely that SR101 has a 
direct effect on neurones while the concentration is still relatively high in the extracellular environment. This 
may also be supported by the striking similarity between the seizure-like LFP activity presented here (Fig. 1), and 
previously published epileptiform activity induced in vivo by application of the compound 4-AP, targeting neu-
ronal potassium channels15. However, recent work have suggested astrocyte involvement in the development of 
epileptic activity15,27,28, and it is conceivable that SR101-induced astrocyte signalling occurs following uptake and 
Figure 2. SR101 can induce seizure-like activity in awake mice. (a) Experimental setup. (b) LFP recordings 
from the same mouse during ketamine/xylazine (KX) anaesthesia and wakefulness. (c) Frequency-domain 
spectra showing change in power distribution between KX anaesthesia and awake LFP from (b). (d) Upper, 
LFP recording showing development of seizure-like activity in primary sensori-motor cortex following 100 μ 
M SR101 loading (10 min incubation). Note that movement artefacts have not been removed from the LFP. 
Lower, frequency power spectrograms from period 1 and 2 from LFP above. (e) Histograms showing individual 
seizure-like activity event amplitudes and intervals.
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contributes to the observed seizure-like LFP activity. Similar, a possible oligodendrocyte-mediated effect cannot 
be excluded, based on the recent finding that SR101 labels oligodendrocytes in vivo6 and the intimate proximity 
between neuronal axon initial segments and myelin sheathes29. Overall, the current knowledge of SR101-evoked 
changes of neuronal excitability and its uptake time course leads us to suggest, for now, that the most likely mech-
anism of action is via a direct effect on neurones, but future experiments should aim to answer this question in 
more detail.
The main purpose of applying SR101 to the cortical surface before initiating 2-photon microscopy experi-
ments, is to label astrocytes in order to unambiguously distinguishing between neuronal and astrocytic sign-
aling in vivo1,4,10,30. Thus, any interference with normal brain physiology mediated by SR101 is in that context 
strongly undesirable. Although, we have not explored the after-effects of SR101-induced seizure-like LFP activ-
ity and its influence on subsequent experiments, other studies indicate that some long-term effects could be 
expected. In our earlier work we showed that ten minutes of SR101 bath application evoke long-term potentia-
tion of synaptic efficacy lasting 80 minutes following exposure in hippocampal slices9. Similar results have been 
reported by Garaschuk showing increased population spike amplitude 50 minutes following SR101 exposure10. 
Overall this suggests, that the exposure of the neuronal tissue to SR101 can cause long-term changes in synaptic 
efficacy of excitatory transmission. In addition, previous observations show that epileptic seizure activity can 
induce long-term synaptic plasticity31,32, as well as increase the expression of the synaptic plasticity-associated 
immediate-early gene c-Fos33,34. Finally, recent work shows that spontaneous interictal epileptiform discharges 
can impair memory consolidation18. Hence, it is a possiblity that the observed 30–40 minutes of abnormal corti-
cal LFP activity (Figs 1 and 2) cause similar changes in synaptic plasticity, and impacts subsequent physiological 
recordings, such as experiments investigating synaptic plasticity in vivo. In agreement with this consideration is 
previous work discussing spontaneous Ca2+ transients in visual cortex before and after injection of 100 μ M SR101 
(described in)10. Here the authors described that SR101 injection initially caused an increase in the frequency of 
Ca2+ transients, supporting our LFP observations (Figs 1 and 2). However, 40 minutes after the SR101 injection 
spontaneous Ca2+ transients were significantly reduced compared to baseline, suggestive of long-term depression. 
Thus, overall, SR101 is able to change cortical synaptic efficacy, on a time scale that impact experimental data 
obtained in vivo.
SR101 was originally discovered to selectively label cortical astrocytes in 20048. Thus, the question arises why 
the potent effects of SR101 concentrations ≥ 100 μ M on cortical LFP activity have not been reported until now. 
Figure 3. Lower SR101 concentrations or shorter incubation time does not evoke abnormal cortical LFP 
activity. (a) Experimental setup. (b) Astrocytic SR101 uptake following cortical 100 μ M (1 min incubation) 
or 50 μ M (10 min incubation) SR101 application (images acquired 60 min following loading). (c) Left, LFP 
recordings following 25 μ M (30 min incubation), 50 μ M (20 min incubation), 100 μ M (1 min incubation) or 
250 μ M (1 min incubation) SR101 application. Right, close-up of LFPs shown on the left. (d) Summary table 
showing main findings.
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As previously described, the main purpose of SR101 application is to label astrocytes to distinguish between 
neuronal- and astrocytic Ca2+ transients. For measuring Ca2+ signals organic Ca2+ indicator dyes, such as Oregon 
Green 488 BAPTA-1 AM, has been widely used1,4,8,30. This Ca2+ indicator dye require ~1 hour following loading to 
reach a stable maximal fluorescence level in stained cells30. In our experiments, we observed that SR101-triggered 
seizure-like LFP activity ceased after 30–40 minutes, depending on the SR101 concentration used (Fig. 1). Thus, 
if SR101 is applied together with an organic Ca2+ indicator dye, and the subsequent experiment is not initiated 
until 1 hour following loading, the abnormal neuronal activity is likely not seen. Furthermore, in our experiments, 
we applied SR101 onto S1-M1 cortical areas, allowing us to observe behavioural outputs, i.e. contra-lateral hind-
limb muscle contractions, during SR101-induced seizure-like LFP activity (Fig. 1, Supplementary Fig. S4 and 
Supplementary Videos S1–3). However, if SR101 is applied to non-motor cortical areas, e.g. visual- or auditory 
cortex, no such obvious behavioural outputs might develop, again masking the abnormal neuronal activity from 
the experimenter.
In summary, we here show that commonly used loading concentrations of the astrocyte-specific indicator 
SR101, i.e. 100 μ M and 250 μ M, can induce seizure-like activity in S1-M1 five to ten minutes following topical 
loading, when incubated for ten minutes. This SR101-induced synchronized cortical activity can evoke motor 
outputs and muscle contractions even in anaesthetised mice. Finally we show, that 25 μ M and 50 μ M SR101 does 
not appear to cause abnormal LFP activity following loading, but still labels cortical astrocytes. Overall, our 
observations may call into question the widespread usage of 100–300 μ M SR101 for topical loading of cortical 
astrocytes, given its potent bioactive effects on cortical tissue when incubated for ten minutes. We advocate that 
SR101 concentrations no higher than 50 μ M should be used for in vivo experiments, to avoid the risk of evoking 
abnormal cortical neuronal activity.
Methods
Animal preparation. All experiments carried out in Rochester were in compliance with the National 
Institute of Health Guide for the Care and Use of Laboratory Animals and in accordance with guidelines approved 
by the institute ethics committee for the care and use of animals. All experiments performed at the University of 
Copenhagen were approved by the Danish National Animal Experiment Committee (Permission No. 2012-15-
2934-00719 and 2015-15-0201-00535) and was in accordance with European Union Regulations.
Mouse preparation was modified from previously published protocol35. Wild-type mice of either sex, 6–12 
weeks old (N = 30), were anaesthetised with an intraperitoneal injection of ketamine (120 mg kg–1) and xyla-
zine (10 mg kg–1) (KX) dissolved in saline. Depth of anaesthesia was monitored by pinch withdrawal reflex 
throughout the experiment. We supplied half the initial dose of KX to the anaesthesia every 60 minutes. If the 
mouse responded to pinch stimulation additional KX anaesthesia was given immediately. Core body temperature 
was monitored by a rectal probe and maintained at 37 ± 0.5 °C by a heating blanket (BS4, Harvard Apparatus). 
Eyes were protected with eye ointment (Stye, NY USA). A custom-made metal plate was glued to the exposed 
and cleaned skull with cyanoacrylate. A craniotomy (2–3 mm in diameter), with the centre 0.5 mm posterior 
to bregma and 3.5 mm lateral from the midline, was prepared over the right or left primary sensori-motor area 
(S1-M1) of the cortex and the dura carefully removed while necessary care was taken to avoid damage the cortical 
tissue (Fig. 1a). The cortical surface was kept moist by topical Ringer solution application (in mM: 126 NaCl, 3.5 
KCl, 1.24 NaH2PO4, 26 NaHCO3, 10 glucose, 2 CaCl2 and 1 MgSO4 at pH 7.4). In a subset of experiments, the 
contra-lateral sciatic nerve was exposed and dissected free from the surrounding tissues (similar to)36, cut distally 
and then mounted on a custom-made hook-electrode (Fig. 1a). We used this arrangement for recording of com-
pound action potentials in the motor axons projecting to skeletal muscles of the distal hindlimb, providing us a 
measure of the timing of cortical output compared with the peripheral motor activity. The skin surrounding the 
exposed muscles and nerves of the hindlimb was sewed to a metal frame forming a bath that was filled with warm 
paraffin oil to reduce current shunting to the bathing media. For the experiments in awake mice (Fig. 2a) we 
adapted a published protocol23. Briefly, mice were anaesthetised using KX, head restrained with a custom-made 
mini-frame glued to the skull with cyanoacrylate and habituated to the restraint over two days, with a total train-
ing duration of 3–4 hours. On the day of the experiment a craniotomy was prepared as described above in iso-
flurane anesthesia, and the mice were allowed to recover from the anaesthesia for 1 hour prior to conducting the 
experiments in order to avoid any after-effects on cortical activity. The mice were during recordings placed in a 
behavioural tube to minimise movement and to comfort the mice (Fig. 2a)23, and the room was kept dark and 
quiet. Body temperature was maintained as described above.
Electrophysiology. We recorded primary sensori-motor cortical layer II (100–150 μ m below the pial sur-
face) local field potentials (LFP) continuously using a NaCl-filled glass micro-electrode (Resistance 2–5 MΩ) 
connected to a DP-311 differential amplifier (Warner Instruments, Hamden, CT, USA). Filters were set at 0.1 Hz 
high-pass and 100 Hz low-pass and sampled at 10 kHz using a power1401 digitiser (Cambridge Electronic Design, 
UK) and Spike2 version 6 (CED, UK) or pCLAMP 9.2 software (Axon Instruments, Sunnyvale, CA, USA). The 
electroneurogram (ENG) was recorded with a custom-made hook-electrode (Fig. 1a) connected to a DP-311 
differential amplifier (Warner instruments, Hamden, USA) and high-pass and low-pass filtered at 1 Hz and 
1 kHz, respectively. The ENG signal was digitised and sampled at 2 kHz using a power1401 digitizer (Cambridge 
Electronic Design, UK) and Spike2 version 6 software (CED, UK).
2-photon in vivo microscopy. For visualising sulforhodamine 101 (SR101) uptake into cortical astrocytes 
in vivo (Figs 1b and 3b) we used 2-photon microscopy as previously described23. We used a custom-built (modi-
fied Olympus Fluoview 300) microscope (Olympus software Fluoview 300) with a 20× water-immersion objec-
tive (NA 0.95, XLUMPLFL20XW, Olympus), linked to a Ti:sapphire laser (Mai Tai, Spectra-Physics). Excitation 
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wavelength was set at 800 nm. The emitted light was separated with an emission filter (ET595/60 Chroma). The 
laser power going into the cortical tissue was in the range of 20–30 mW37.
Dye application. SR101 (Molecular Probes, S359) was dissolved in Ringer solution to concentrations of 25 μ M, 
50 μ M, 100 μ M or 250 μ M, all within the range for what is used in the litterature4,15,19,20 (see Supplementary Table S1). 
In some experiments we tested Texas Red (Dextran, Molecular Probes, D1863), a tissue fixable analog of SR101, 
at concentrations of 100 μ M or 500 μ M. The dissolved dye was topically applied to the exposed dura-free cortical 
surface. Right before application of the dye, the Ringer solution bathing the craniotomy was carefully absorbed. 
The dye solution was then applied using a pipette onto the exposed cortex to cover the cranial window. The SR101 
was kept on the cortical surface for 1, 10, 20 or 30 min, depending on the concentration used, all incubation 
durations were within the range for what is used in the literature (see Supplementary Table S1), and carefully 
washed away using Ringer solution (see Supplementary Fig. S3). Only one SR101 concentration was used in each 
experiment. In four experiments we pressure ejected the SR101 (1 min pulse, 120–200 mbar; 100 μ M SR101) onto 
the cortical surface under agarose (1.5%, Sigma) and a glass coverslip. This approach enabled us to image the 
time course of astrocytic SR101 uptake using 2-photon microscopy (Fig. 1b). To eliminate the possibility that our 
experimental observations resulted from a contaminated batch of SR101 we used several different SR101 batches 
over the course of many months, all were bought from Molecular Probes.
LFP analysis. Power measurements. LFP processing and analysis was performed using MATLAB (2015a, 
The MathWorks, Massachusetts, United States). First, any 50 Hz or 60 Hz line noise were removed from the 
recording using the rmlinesc function, available from the Chronux 2.0, an open-source, MATLAB-based, 
data analysis toolbox available at http://chronux.org/38. The de-noised LFP was then down sampled to 1kHz 
using the resample function in MATLAB. LFP traces chosen for power spectral analysis was then normalized 
to the z-score18 by subtracting the mean and dividing by the standard deviation of the LFP during the entire 
LFP recording. For exploring the frequency-domain dynamics in LFPs we used the mtspectrumc function, a 
multitaper method implemented in the Chronux 2.0 toolbox38. For this analysis we used a padding factor of 
-1, time-bandwidth product of 3 and 5 tapers. For the frequency-domain graphs (Fig. 2c and Supplementary 
Fig. S1) a moving average and moving standard deviation with a window size of 50 was applied afterwards. For 
Supplementary Fig. S7 no moving average or moving standard deviation was applied, in order to show the raw 
frequency-domain dyamics. For Supplementary Fig. S1f the average power (in decibel) was determined for delta 
(1–4 Hz) and beta (12–30 Hz) LFP bands within period 1 (i.e. baseline) and period 2 (i.e. SR101-induced LFP 
activity) for both anaesthetised and awake recordings. The relative change in power density (i.e. period 2 vs period 
1, reported in % of baseline) was then determined for both anaesthetised and awake recording. Time-frequency 
spectrograms were constructed using the multitaper method implemented in the mtspecgramc function in the 
Chronux 2.0 toolbox38. For this analysis we used a padding factor of −1, a moving window of 2.5 s in duration 
with a slide of 50 ms along the time axis and time-bandwidth product of 3 and 5 tapers. All power measurements 
are reported in units of decibel (dB) unless otherwise stated.
Event detection. For determining the individual event amplitude and event intervals for the synchronized cor-
tical seizure-like activity (Figs 1d and 2e) we used custom-made procedures in MATLAB. First a threshold was 
determined as 4 standard deviations (S.D.) more negative than the mean LFP during baseline (first 5 min of 
recording) and synchronized cortical seizure-like events were located using this threshold. Next the amplitude 
and event interval was determined for all of the events in the recording. Amplitudes and event intervals across 
experiments were pooled and histograms produced using the histogram function with 40 bins in MATLAB. We 
determined the synchronized cortical seizure-like activity onset and cessation relative to topical application of 
either 100 μ M or 250 μ M SR101 (Fig. 1e and Supplementary Fig. S2) using custom-made procedures in MATLAB. 
For this we determined time-points for the first and last seizure-like event in a recording using a threshold deter-
mined as 4 standard deviations more negative than the mean LFP during baseline (first 5 min of recording) and 
calculated the delta times from the time-point of SR101 application.
Correlation between LFP and ENG events. For determining the correlation between seizure-like events and ENG 
compound action potential events (Fig. 1f and Supplementary Fig. S4) we first determined the time-points for all 
the seizure-like events in a recording and converted the LFP recording into binaries, i.e. 0 if no seizure-like event 
and 1 if seizure-like event was present, using a threshold determined as 4 S.D. more negative than the mean LFP 
during baseline (first 5 min of recording). Next we screened the ENG recording for the presence of compound 
action potentials, using a threshold as 4 S.D. from the mean ENG during baseline (first 5 min of recording), in the 
time windows corresponding to where the binary LFP was 1. If ENG compound action potentials were present 
in the time window, that window was assigned 1 and if no compound action potentials were present assigned 0. 
Afterwards, we plotted the cumulative number of seizure-like LFP events versus the cumulative number of ENG 
compound action potential events at those time points and calculated the linear correlation using a Pearsons’s 
correlation test (Fig. 1f).
Statistics. Our preliminary experiments suggested the existence of very large LFP changes from topical 
SR101 application. We therefore used the smallest number of mice that is neccesary to compare statistically 
based on power analysis considering that all mice exposed to 100 μ M and 250 μ M SR101 for 10 min developed 
seizure-like activity, which was not observed in any control experiments (see Supplementary Fig. S2). Statistical 
comparison between relative onsets- and cessation of seizure-like activity between 100 μ M and 250 μ M SR101 
was assessed using a two-sided Welch’s t-test (Fig. 1d). This test was chosen due to the violation of the Student’s 
t-test assumptions, i.e. equal variances and sample sizes39. Statistical comparision for power spectral density in 
www.nature.com/scientificreports/
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1–4 Hz and 12–30 Hz LFP bands during baseline compared to during SR101-induced seizure-like activity was 
assessed using a paired Student’s t-test. We considered significant tests with P < 0.05. Exact P-values are reported 
unless smaller than 0.0001. For calculating the linear correlation between the cumulative number of seizure-like 
LFP events versus the cumulative number of ENG compound action potential events we used the Pearsons’s cor-
relation test and reported the R2-value (Fig. 1e). Data is plotted as mean ± S.D. where appropriate. Figures were 
created with Illustrator CC 19.2.1 (Adobe, USA).
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